64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) (SECuRE)

• ClinicalTrials.gov Identifier: NCT04868604
• Recruitment Status: Recruiting
• First Posted: May 3, 2021
• Last Update Posted: March 27, 2024
• Sponsor: Clarity Pharmaceuticals Ltd
• Information provided by (Responsible Party): Clarity Pharmaceuticals Ltd

Study Description

Brief Summary:

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Condition or disease	Intervention/treatment	Phase
Prostatic Neoplasms, Castration-Resistant	Drug: 64Cu-SAR-bisPSMA; Drug: 67Cu-SAR-bisPSMA	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 44 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: This study is to be conducted in 3 phases, a dosimetry phase, a dose escalation phase and a cohort expansion phase.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
• Actual Study Start Date: August 11, 2021
• Estimated Primary Completion Date: September 2026
• Estimated Study Completion Date: September 2026

Arms and Interventions

Arm

Intervention/treatment

Experimental: 67Cu-SAR-bisPSMA; In the dosimetry phase patients will receive a single 200 MBq administration of 64Cu-SAR-bisPSMA. In the dose escalation phase patients will receive up to 2 administrations of 200 MBq of 64Cu-SAR-bisPSMA. In the cohort expansion phase patients will receive up to 3 administrations of 200 MBq of 64Cu-SAR-bisPSMA. In the dose escalation phase patients will receive up to 2 administrations of 67Cu-SAR-bisPSMA (dose will be determined based on cohort allocation). In the cohort expansion phase patients will receive 2 administrations of 67Cu-SAR-bisPSMA at the recommended dose level determined through dose escalation.

Drug: 64Cu-SAR-bisPSMA; 64Cu-SAR-bisPSMA; Drug: 67Cu-SAR-bisPSMA; 67Cu-SAR-bisPSMA

Outcome Measures

Primary Outcome Measures :

1. Biodistribution of 64Cu-SAR-bisPSMA [ Time Frame: 48 hours ]
   Biodistribution will be calculated by utilizing the PET/CT scans.
2. Dosimetry of 64Cu-SAR-bisPSMA [ Time Frame: 48 hours ]
   Dosimetry will be calculated by utilizing the PET/CT scans.
3. Modelling of 67Cu-SAR-bisPSMA dosimetry utilizing the 64Cu-SAR-bisPSMA PET/CT scans [ Time Frame: 48 hours ]
   Dosimetry will be calculated by utilizing the PET/CT scans.
4. Maximum Tolerated Dose (MTD) or Maximum Feasible Dose of a single dose of 67Cu-SAR-bisPSMA [ Time Frame: 8 weeks ]
   MDT as determined by cohort observations of dose limiting toxicities (DLT)
5. Recommended dose of two doses of 67Cu-SAR-bisPSMA [ Time Frame: 14 weeks ]
   Recommended dose as determined by cohort observations of DLTs
6. Efficacy of 67Cu-SAR-bisPSMA in terms of Prostate specific Antigen (PSA) response [ Time Frame: Up to 5 years ]
   Proportion of participants with ≥50% decline in PSA
7. Efficacy of 67Cu-SAR-bisPSMA in terms of radiographic response [ Time Frame: Up to 5 years ]
   Efficacy will be assessed via the overall response rate according to RECIST V1.1 for soft tissue disease and according PCWG3 for bone lesions
8. Incidence of 67Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Up to 5 years ]
   Adverse Events will be as assessed by CTCAE version 5.00
9. Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in Vital Signs [ Time Frame: Up to 1 year ]
   Change from baseline in vital signs
10. Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in electrocardiogram (ECG) parameters [ Time Frame: Up to 24 weeks ]
    Change from baseline in ECG parameters
11. Safety and tolerability of 67Cu-SAR-bisPSMA: Number of Participants With Changes from baseline in laboratory results [ Time Frame: Up to 22 weeks ]
    Change from baseline in laboratory results
12. Incidence of 64Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Up to 5 years ]
    Adverse Events will be as assessed by CTCAE version 5.00

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Signed informed consent;
• ≥18 years of age;
• Eastern Cooperative Oncology Group performance status of 0 to 2;
• Life expectancy >6 months;
• Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa);
• Positive 64Cu-SAR-bisPSMA PET/CT scan, where 64Cu-SAR-bisPSMA uptake (standardized uptake value [SUV] max) of at least 1 known lesion is higher than that of the liver on the 1 hour positron emission tomography (PET)/computed tomography (CT) scan;
• Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L);

• Have progressive metastatic castration-resistant prostate cancer (mCRPC) despite prior androgen deprivation therapy and at least either enzalutamide and/or abiraterone (or other such androgen receptor pathway inhibitors). Documented progressive mCRPC will be based on at least 1 of the following criteria:

  1. Serum/plasma prostate specific antigen (PSA) progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal value for study enrollment is 2.0 ng/mL;
  2. Soft-tissue progression defined as a ≥20% increase in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since the last treatment directed at the metastatic cancer has started (not including hormonal therapy) or the appearance of 1 or more new lesions;
  3. Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan.
• ≥1 metastatic lesion that is present at screening CT, magnetic resonance imaging (MRI), or bone scan imaging obtained ≤28 days prior to enrollment into the study;
• Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (prior chemotherapy, radiation, immunotherapy, etc.);

• Participants must have adequate organ function:

  • Bone marrow reserve:

    • White blood cell (WBC) count ≥2.5 x 109/L (2.5 x 109/L is equivalent to 2.5 x 103/μL and 2.5 x K/μL and 2.5 x 103/cc and 2500/μL) OR
    • Absolute neutrophil count (ANC) ≥1.5 x 109 /L (1.5 x 109 /L is equivalent to 1.5 x 103 /μL and 1.5 x K/μL and 1.5 x 103 /cc and 1500/μL);
  • Platelets ≥100 x 109 /L (100 x 109 /L is equivalent to 100 x 103 /μL and 100 x K/μL and 100 x 103 /cc and 100,000/μL);
  • Hemoglobin ≥9 g/dL (5.59 mmol/L);
  • Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3 x ULN is permitted;
  • Alanine aminotransferase or aspartate aminotransferase ≤3.0 x ULN OR ≤5.0 x ULN for participants with liver metastases;
  • Creatinine clearance or estimated glomerular filtration rate ≥50 mL/min
• For participants who are human immunodeficiency virus infected: Participant must be healthy and have a low risk of Acquired Immune Deficiency Syndrome related outcomes in the opinion of the Investigator;
• For participants who have partners of childbearing potential: Partner and/or participant must use a method of birth control with adequate barrier protection.

Exclusion Criteria:

• Major surgery within 12 weeks prior to enrollment into the study;
• Brain metastasis;
• Histologic diagnosis of small cell or neuroendocrine prostate cancer;
• Prior history of leukemia or Myelodysplastic Syndrome;
• Diagnosis of Deep Vein Thrombosis or Pulmonary Embolism within 4 weeks prior to enrollment into the study;
• Unmanageable urinary tract obstruction;
• Evidence of progressive lesion(s) on MRI and/or CT (according to Response Evaluation Criteria in Solid Tumors V1.1) that is prostate-specific membrane antigen (PSMA) negative on the 1 hour 64Cu-SAR-bisPSMA PET/CT scan as determined at screening;
• Previous treatment with a systemic radionuclide, including 177Lu, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Actinium-225, Iodine-131 within 6 months or in case of Radium-223 within 3 months of treatment initiation (Day 0) without prior approval of the medical monitor;
• Previous treatment with any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 4 weeks prior to treatment on study with the exception of Luteinizing Hormone Releasing Hormone, any other androgen deprivation therapy (ADT) (if ADT is discontinued prior to enrolment, 14 days must elapse after abiraterone discontinuation and 28 days after enzalutamide before participant can be enrolled) or low dose corticosteroids;
• Previous treatment with any investigational agents within 4 weeks prior enrollment into the study;
• Known hypersensitivity to the components of the investigational products or its analogues;
• Transfusion for the sole purpose of making a participant eligible for study inclusion;
• Spinal metastasis with symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression;
• Concurrent serious medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation;
• Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer, superficial bladder cancer;
• Any condition or personal situation that would pose an unacceptable radiation safety risk (as per institution guidelines, state and/or national regulations) to the participant or carer at the time of release following the completion of therapy (e.g. uncontrolled urinary incontinence, high dependency care);
• Participants in whom it is known that external beam radiation therapy is scheduled after enrollment into the study.

Contacts and Locations

Contacts

Contact: Clarity Pharmaceuticals; +61 (0) 2 9209 4037; clinicaltrials@claritypharmaceuticals.com

Locations

United States, California

Stanford Cancer Institute; Recruiting

Stanford, California, United States, 94305

Contact: David Marcellus

Principal Investigator: Hong Song, MD

United States, Minnesota

Mayo Clinic; Recruiting

Rochester, Minnesota, United States, 55905

Principal Investigator: Geoffrey Johnson, MD

United States, Missouri

Washington University School of Medicine at Barnes-Jewish Hospital; Recruiting

Saint Louis, Missouri, United States, 63110

Principal Investigator: Vikas Prasad, MD

United States, Nebraska

GU Research Network; Recruiting

Omaha, Nebraska, United States, 68130

Contact: Tony Romero 402-690-3716 tromero@gucancer.com

Principal Investigator: Luke Nordquist, MD

United States, New York

Weill Cornell Medicine at New York-Presbyterian; Recruiting

New York, New York, United States, 10021

Principal Investigator: Scott Tagawa, MD

Sponsors and Collaborators

Clarity Pharmaceuticals Ltd

Investigators

• Study Director: Clarity Pharmaceuticals; Clarity Pharmaceuticals

More Information

• Responsible Party: Clarity Pharmaceuticals Ltd
• ClinicalTrials.gov Identifier: NCT04868604
• Other Study ID Numbers: CLP05
• First Posted: May 3, 2021
• Last Update Posted: March 27, 2024
• Last Verified: March 2024

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases